Hormonal
Elevated intracellular ceramide levels induce cellular senescence and contribute to age-related pathologies such as insulin resistance and atherosclerosis, whereas sphingosine-1-phosphate (S1P) delays senescence and promotes cell survival.
This research highlights that cellular aging is driven by specific lipid signals: high ceramide promotes aging/senescence, while S1P promotes youth/survival. While this paper does not prescribe a specific diet, it implies that interventions which lower ceramide or boost S1P (potentially through specific dietary fats or metabolic health) could theoretically delay aging. Focus on metabolic health to maintain favorable sphingolipid balances.
Sphingolipids are bioactive molecules that regulate cell biology and fate such as cell cycle, senescence, proliferation, and migration... ceramide induces cellular senescence and sphingosine-1–phosphate delays it.
Why this rating
The paper is a comprehensive review citing multiple studies across various organisms (yeast, worms, flies, mice) and human cell lines, establishing strong consensus on the roles of Cer and S1P.
Source
Role of sphingolipids in senescence: implication in aging and age-related diseases
Magali Trayssac et al. · Journal of Clinical Investigation · 2018
DOI 10.1172/jci97949
More from this paper
- Inhibition of sphingolipid synthesis (specifically via SPT inhibition by myriocin or CerS inhibition by fumonisin B1) extends lifespan in model organisms like yeast and C. elegans, suggesting that reducing ceramide production can delay aging.Good
- Ceramide accumulation in specific tissues (adipose, liver, muscle) during aging and high-fat diet consumption drives insulin resistance and inflammation, linking sphingolipid metabolism to type 2 diabetes.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →